Aytu Biopharma (AYTU) Asset Writedowns and Impairment (2020 - 2026)

Aytu Biopharma (AYTU) has 7 years of Asset Writedowns and Impairment data on file, last reported at $700000.0 in Q1 2026.

• On a quarterly basis, Asset Writedowns and Impairment rose 600.0% year-over-year to $700000.0 in Q1 2026; TTM through Mar 2026 was $1.9 million, a 40.24% increase from a year earlier, with the FY2025 full-year figure at $325000.0, down 72.67% from the prior year.
• Asset Writedowns and Impairment for Q1 2026 stood at $700000.0, down from $800000.0 in the prior quarter.
• Over the last five years, Asset Writedowns and Impairment for AYTU reached as high as $45.2 million in Q1 2022 and fell as low as -$62.5 million in Q2 2022.
• Historically, Asset Writedowns and Impairment has averaged -$551562.5 across 5 years, with a median of $112500.0 in 2023.
• On a YoY basis, Asset Writedowns and Impairment climbed as much as 2500.0% in 2022 and fell as far as 1598.29% in 2022.
• Year by year, Asset Writedowns and Impairment stood at $2.6 million in 2022, then sank by 96.15% to $100000.0 in 2023, then changed by 0.0% to $100000.0 in 2024, then soared by 700.0% to $800000.0 in 2025, then slipped by 12.5% to $700000.0 in 2026.
• Per Business Quant data, the three most recent Asset Writedowns and Impairment figures were $700000.0 in Q1 2026, $800000.0 in Q4 2025, and $278000.0 in Q3 2025.